Insider Selling: Beta Bionics (NASDAQ:BBNX) Insider Sells 2,650 Shares of Stock

Beta Bionics, Inc. (NASDAQ:BBNX) insider Mike Mensinger sold 2,650 shares of Beta Bionics stock in a transaction on Tuesday, October 27th. The stock was sold at an average price of $22.00, for a total transaction of $58,300.00. Following the sale, the insider directly owned 174,740 shares of the company’s stock, valued at $3,844,280. This represents a 1.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Mike Mensinger also recently made the following trade(s):

• On Wednesday, September 16th, Mike Mensinger sold 2,650 shares of Beta Bionics stock. The shares were sold at an average price of $22.00, for a total transaction of $58,300.00.
• On Wednesday, September 2nd, Mike Mensinger sold 4,375 shares of Beta Bionics stock. The shares were sold at an average price of $19.11, for a total value of $83,606.25.

Beta Bionics Trading Down 1.5%

Shares of NASDAQ:BBNX traded down $0.27 during midday trading on Thursday, hitting $17.58. The company had a trading volume of 1,288,471 shares, compared to its average volume of 1,185,205. Beta Bionics, Inc. has a 12 month low of $8.80 and a 12 month high of $32.71. The stock has a market cap of $790.92 million, a price-to-earnings ratio of -10.65 and a beta of 3.39. The firm has a fifty day simple moving average of $19.21 and a 200 day simple moving average of $14.90.

Beta Bionics (NASDAQ:BBNX) last released its quarterly earnings data on Tuesday, October 27th. The company reported ($0.52) EPS for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.01. Beta Bionics had a negative return on equity of 26.30% and a negative net margin of 61.31%. The business had revenue of $35.51 million during the quarter. Equities analysts forecast that Beta Bionics, Inc. will post -2.02 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently weighed in on BBNX shares. Wall Street Zen upgraded shares of Beta Bionics from a “sell” rating to a “hold” rating in a research report on Saturday, September 19th. Piper Sandler reissued an “overweight” rating and set a $24.00 price objective (up from $20.00) on shares of Beta Bionics in a research note on Wednesday. UBS Group restated a “buy” rating and set a $25.00 price objective on shares of Beta Bionics in a report on Tuesday, September 15th. Truist Financial upped their target price on shares of Beta Bionics from $23.00 to $28.00 and gave the company a “buy” rating in a research note on Thursday, September 24th. Finally, The Goldman Sachs Group increased their target price on shares of Beta Bionics from $17.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $23.69.

More Beta Bionics News

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Analyst support remains favorable. Stifel Nicolaus reiterated its “Buy” rating. The broader analyst consensus remains “Moderate Buy,” with an average price target above the current trading level. Stifel Nicolaus Buy Rating
• Positive Sentiment: Third-quarter results modestly beat expectations. Beta Bionics reported a loss of $0.52 per share versus the expected $0.53 loss, while revenue of $35.51 million exceeded estimates of approximately $34.7 million. The company also updated its full-year 2026 outlook, although the available reports did not provide all guidance details. Beta Bionics Third-Quarter Results
• Neutral Sentiment: Insider selling adds a modest cautionary signal. Director Mark Hopman sold 821 shares for approximately $16,420, reducing his direct ownership by about 1.48%. The sale was relatively small compared with his remaining holdings, but it follows several earlier sales. SEC Insider Filing
• Negative Sentiment: Multiple law firms are publicizing a securities class action. The case covers investors who purchased BBNX securities between July 30, 2025, and February 24, 2026, with a November 3 deadline to seek lead-plaintiff status. Although the allegations remain unproven, the volume of notices increases legal and reputational risk. Beta Bionics Shareholder Lawsuit Alert
• Negative Sentiment: The lawsuit centers on alleged FDA and iLet disclosure issues. Plaintiffs allege that Beta Bionics inadequately disclosed FDA quality-system findings and potentially serious iLet-related complaints. Further regulatory action, product remediation, litigation expenses or damage to customer confidence could weigh on future growth and valuation. Beta Bionics FDA Compliance Lawsuit
• Negative Sentiment: Execution risks could affect the planned Mint patch-pump launch. Investors remain concerned about commercialization, manufacturing and regulatory execution for the company’s next-generation product, potentially limiting the benefit of the quarterly revenue beat. Beta Bionics Mint Pump Execution Risks

Institutional Investors Weigh In On Beta Bionics

Institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new position in shares of Beta Bionics during the 2nd quarter worth about $52,340,000. Eversept Partners LP lifted its holdings in Beta Bionics by 108.6% during the 1st quarter. Eversept Partners LP now owns 1,414,838 shares of the company’s stock valued at $14,177,000 after purchasing an additional 736,576 shares during the last quarter. Bank of America Corp DE acquired a new position in shares of Beta Bionics in the second quarter valued at $8,566,000. Perceptive Advisors LLC lifted its stake in shares of Beta Bionics by 39.8% during the 1st quarter. Perceptive Advisors LLC now owns 842,944 shares of the company’s stock worth $8,446,000 after buying an additional 240,000 shares during the last quarter. Finally, Bruce & Co. Inc. acquired a new stake in shares of Beta Bionics during the 1st quarter worth about $5,518,000.

Beta Bionics Company Profile

Beta Bionics, Inc (NASDAQ: BBNX) is a medical technology company focused on developing and commercializing automated insulin-delivery systems for people with insulin-dependent diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to help manage blood glucose levels with limited user input.

The iLet Bionic Pancreas combines a wearable insulin pump with continuous glucose monitoring technology and adaptive dosing algorithms. The system is designed to automatically adjust insulin delivery based on an individual’s glucose readings and requires users to provide relatively simple meal announcements rather than calculate precise carbohydrate amounts.